RecruitingPhase 1NCT06413953

A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors

A Phase I Clinical Study of Tolerability and Pharmacokinetics of TQB3107 Tablets in Patients With Malignant Tumors

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Enrollment

140 participants

Start Date

Jun 27, 2024

Study Type

INTERVENTIONAL

Conditions

Advanced cancers

Summary

TQB3107 is an target inhibitor that binds to target to induce apoptosis and inhibits the proliferation of a variety of tumor cells. This is a clinical study to evaluate the safety and tolerability of TQB3107 tablets in subjects with advanced malignancies, to determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) (if any), and the recommended dose for Phase II (RP2D).

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called TQB3107 Tablets for people with advanced cancers. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTQB3107 Tablets

TQB3107 Tablets is a selective target inhibitor.

Locations(12)

Sun Yat-sen University Cancer Cen

Guangzhou, Guangdong, China

The Fifth Affiliated Hospital Sun Yat-sen University

Zhuhai, Guangdong, China

The Affiliated Hospital of Chengde Medical College

Chengde, Hebei, China

Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, China

Hunan Cancer Hospital

Changsha, Hunan, China

The First People's Hospital Of Changzhou

Changzhou, Jiangsu, China

Shandong Medical And Pharmaceutical University Hospital

Binzhou, Shandong, China

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

West China Hospital，Sichuan University

Chengdu, Sichuan, China

The Affiliated Hospital of Southwest Medical University

Luzhou, Sichuan, China

Tianjin Municipality Locations

Tianjin, Tianjin Municipality, China

The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06413953

Related Trials

Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers

NCT0726070811 locations